No Data
No Data
No Data
No Data
No Data
Analysts Offer Insights on Healthcare Companies: EFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
TipRanksApr 5 18:30
TianYan Pharmaceutical Announces 2023 Annual Financial Results and Company Progress
-Masking anti-CTLA-4 safety antibody SafeBody ADG126 (muzastotug) combined with anti-PD-1 for metastatic microsatellite-stabilized (MSS) colorectal cancer (CRC) treatment has proven its clinical benefits in higher dose and higher frequency multiple-dose regimens. The data highlights the potential best in class -- Expanding the ongoing combined dose expansion cohort for MSS CRC phase 2 and PD-1 to more than 50 patients, including initiating a new 20 mg/kg starting negative dose group in 2024
PR NewswireApr 1 16:18
Adagene Inc. Strikes Deal to Sell Depositary Shares
TipRanksMar 30 03:57
Adagene ADR Non-GAAP EPS of -$0.21, Revenue of $18.11M
Seeking AlphaMar 30 00:47
Adagene's Breakthroughs Promise Future Growth
TipRanksMar 29 21:57
Press Release: Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - Data for masked anti-CTLA-4 SAFEbody(R) ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate
Dow JonesMar 29 21:00
No Data
No Data